ROIV · Intrinsic value
Is Roivant Sciences Ltd. (ROIV) overvalued or undervalued?
TickerWorth's dcf fair value for Roivant Sciences Ltd. (ROIV) is $1.16 a share, against the delayed market price of $34.37 (2875% above fair value), as of Oct 19, 2026. no growth rate up to 300%/yr justifies the price under these economics It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is ROIV overvalued?
- DCF fair value
- $1.16
- Market price
- $34.37
- Downside to fair value
- 96.6%
- Verdict
- 2875% above fair value
Reverse DCF, on our cash-flow model rather than the fair value above: no growth rate up to 300%/yr justifies the price under these economics
What is ROIV's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 24 of 100
Cheaper than 24% of Healthcare companies in US
- Price vs worth · — of 100
- Quality · 17 of 100
More profitable than 17% of Healthcare companies in US
- Financial health · 70 of 100
Financially stronger than 70% of Healthcare companies in US
- Growth · 6 of 100
Growing faster than 6% of Healthcare companies in US
- Momentum · 65 of 100
Outperformed 65% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
ROIV DCF valuation: what the price assumes
At a recent price of $34.37, Roivant Sciences Ltd. (ROIV) trades 2875% above TickerWorth's base-case discounted-cash-flow (DCF) fair value of $1.16 per share — meaning the market currently prices ROIV overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -96.6% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
The valuation discounts Roivant Sciences Ltd.'s projected free cash flows at a weighted-average cost of capital (WACC) of 10.5%, with a long-run terminal growth rate of 2.5%. About 64% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, ROIV's modeled DCF value ranges from about $-0.36 to $1.96 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Roivant Sciences Ltd. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of ROIV's intrinsic value. Figures update as new filings and prices come in.
Every input behind ROIV's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $7,530,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 2.0% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | -10% → -6% → -3% → 0% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.12 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 722M |
| Market priceDelayed quote · as of 2026-10-19 16:18 UTC | $34.37 |
Change ROIV's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Roivant Sciences Ltd. do?
What does it do?
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. It operates in the Biotechnology industry (Healthcare sector), headquartered in United Kingdom. The company employs roughly 721 people.
How does it make money?
The business turns $8M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -25408.1%), after a 0% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries heavy debt (2.2× equity), comfortably covers its short-term bills (16.7× current ratio), and is currently lossmaking.
Who at ROIV filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10% owner | Disposition to issuer | $44,836,915.00 | Form 4 for Roivant Sciences Ltd. (opens sec.gov in a new tab) | |
| Epperly Melissa B, | Director | Option exercise | $79,165.00 | Form 4 for Epperly Melissa B, (opens sec.gov in a new tab) | |
| Epperly Melissa B, | Director | Open-market sale | $607,948.00 | Form 4 for Epperly Melissa B, (opens sec.gov in a new tab) | |
| Epperly Melissa B, | Director | Open-market sale | $32,913.00 | Form 4 for Epperly Melissa B, (opens sec.gov in a new tab) | |
| Gline Matthew | Director, CEO | Shares withheld (tax) | $2,785,573.47 | Form 4 for Gline Matthew (opens sec.gov in a new tab) | |
| Torti Frank | President and Vant Chair | Shares withheld (tax) | $1,474,100.13 | Form 4 for Torti Frank (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is ROIV's intrinsic value?
TickerWorth's base-case DCF fair value for Roivant Sciences Ltd. (ROIV) is $1.16 per share, versus a market price of $34.37 (2875% above fair value).
Is ROIV overvalued or undervalued?
On our DCF model ROIV looks overvalued vs fair value at $34.37. This is an educational estimate, not advice.
What discount rate is used for ROIV?
A WACC of 10.5% and a terminal growth rate of 2.5%.
Is Roivant Sciences stock undervalued?
TickerWorth's dcf fair value for Roivant Sciences Ltd. (ROIV) is $1.16 against a market price of $34.37. Our read: 2875% above fair value. This is a model estimate, not investment advice.
Roivant Sciences (ROIV) DCF valuation and fair value
Our dcf fair value for Roivant Sciences Ltd. (ROIV) is $1.16, built on a 10.5% discount rate (WACC) and 2.5% terminal growth. Every assumption is listed on this page with its source.
What growth is priced into Roivant Sciences stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $34.37. A model estimate, not investment advice.
Roivant Sciences (ROIV) insider trading
The most recent insider filing (SEC Form 4) for Roivant Sciences Ltd. (ROIV): Roivant Sciences Ltd., Director, 10% owner, disposition to issuer on 2026-10-01. The latest filings are listed on this page. A disclosure, not a signal to trade.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.